Rationale: Rifampin at a dose of 10 mg/kg was introduced in 1971 based on pharmacokinetic,
toxicity, and cost considerations. Available data in mice and humans showed that an …

The World Health Organization (WHO) recommends that countries implement pharmacovigilance
and collect information on active drug safety monitoring (aDSM) and management of …

MDR TB living in this region may be much higher because a substantial proportion of patients
are never screened for drug-resistant TB before starting treatment, partly because of a lack …

Multidrug- and extensively drug-resistant tuberculosis have emerged as grave threats to public
health worldwide. Very few active drugs are available or likely to become available soon. …

In the Netherlands, 1.4% of tuberculosis (TB) cases are caused by Mycobacterium bovis.
After we admitted 3 patients with M. bovis infections to our reference hospital, we conducted a …

Background Allergic bronchopulmonary aspergillosis ( ABPA ) is characterised by an exaggerated
Th2 response to A spergillus fumigatus, but the immunological pathways responsible …

Treatment Outcomes in Multidrug-Resistant Tuberculosis | NEJM Skip to main content NEJM
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …

Background Non-tuberculous mycobacteria (NTM) infections are hard to treat. New
antimicrobial drugs and smarter combination regimens are needed. Objectives Our aim was to …

Background Recent evidence suggests that higher rifampicin doses may improve tuberculosis
(TB) treatment outcome. Methods In this observational cohort study we evaluated all TB …

Introduction Tuberculosis (TB) is the leading cause of death due to an infectious disease
worldwide. Especially in low-income countries, new diagnostic techniques that are accessible, …